Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

被引：227

作者：

Goetz, Matthew P. ^{[1
]}

Sangkuhl, Katrin ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

Schwab, Matthias ^{[4
,5
,6
]}

Province, Michael ^{[7
]}

Whirl-Carrillo, Michelle ^{[2
]}

Symmans, W. Fraser ^{[8
]}

McLeod, Howard L. ^{[9
]}

Ratain, Mark J. ^{[10
]}

Zembutsu, Hitoshi ^{[11
]}

Gaedigk, Andrea ^{[12
,13
]}

van Schaik, Ron H. ^{[14
,15
]}

Ingle, James N. ^{[1
]}

Caudle, Kelly E. ^{[16
]}

Klein, Teri E. ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany

[7] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA

[11] Natl Canc Ctr, Div Human Genet, Res Inst, Tokyo, Japan

[12] Univ Missouri, Div Clin Pharmacol Toxicol & Therapeut Innovat, Childrens Mercy Kansas City, Kansas City, MO 64110 USA

[13] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[14] Erasmus MC, Int Expertctr Pharmacogenet, Dept Clin Chem, Rotterdam, Netherlands

[15] LKCH UMC Utrecht, Utrecht, Netherlands

[16] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; ESTROGEN-RECEPTOR; IN-VITRO; POSTMENOPAUSAL WOMEN; ACTIVE METABOLITE; CODEINE THERAPY; GENOTYPE; CYP2C19-ASTERISK-2; POLYMORPHISMS;

D O I：

10.1002/cpt.1007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

引用

页码：770 / 777

页数：8

共 57 条

[1] EVIDENCE FOR THE METABOLIC-ACTIVATION OF NON-STEROIDAL ANTIOESTROGENS - A STUDY OF STRUCTURE-ACTIVITY-RELATIONSHIPS
ALLEN, KE
CLARK, ER
JORDAN, VC
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 1980, 71 (01) : 83 - 91
[2] Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis
Bai, Lan
He, Juan
He, Gong-Hao
He, Jian-Chang
Xu, Fan
Xu, Gui-Li
[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (19) : 8331 - 8335
[3] CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
Beelen, K.
Opdam, M.
Severson, T. M.
Koornstra, R. H. T.
Vincent, A. D.
Hauptmann, M.
van Schaik, R. H. N.
Berns, E. M. J. J.
Vermorken, J. B.
van Diest, P. J.
Linn, S. C.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 649 - 655
[4] BORGNA JL, 1981, J BIOL CHEM, V256, P859
[5] Clinical Pharmacogenetics Implementation Consortium (CPIC), CPIC GUID TAM BAS CY
[6] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Leeder, J. S.
Klein, T. E.
Caudle, K. E.
Haidar, C. E.
Shen, D. D.
Callaghan, J. T.
Sadhasivam, S.
Prows, C. A.
Kharasch, E. D.
Skaar, T. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) : 376 - 382
[7] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Klein, T. E.
Shen, D. D.
Callaghan, J. T.
Kharasch, E. D.
Skaar, T. C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (02) : 321 - 326
[8] CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
Damkier, Per
Kjaersgaard, Anders
Barker, Kimberly A.
Cronin-Fenton, Deidre
Crawford, Anatasha
Hellberg, Ylva
Janssen, Emilius A. M.
Langefeld, Carl
Ahern, Thomas P.
Lash, Timothy L.
[J]. SCIENTIFIC REPORTS, 2017, 7
[9] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Davies, C.
Godwin, J.
Gray, R.
Clarke, M.
Darby, S.
McGale, P.
Wang, Y. C.
Peto, R.
Pan, H. C.
Cutter, D.
Taylor, C.
Ingle, J.
[J]. LANCET, 2011, 378 (9793) : 771 - 784
[10] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Desta, Z
Ward, BA
Soukhova, NV
Flockhart, DA
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) : 1062 - 1075

← 1 2 3 4 5 6 →